A r t i c l e s Several SMCs are being evaluated in early-to mid-stage clinical trials in cancer patients 1 . SMCs are rationally designed based on the properties of Smac, an endogenous pro-apoptotic protein that, upon release from the mitochondria, binds to and antagonizes several members of the IAP family. The IAP proteins are attractive cancer therapy targets because they regulate programmed cell death in tumor cells 1 . For example, the prototypical X-linked IAP (XIAP) protein, which directly inhibits key initiator and executioner caspase proteins within every programmed cell death cascade and can thereby thwart the completion of all cell death programs, is hyperactive in many human cancers 1, 2 . In addition, genetic loss of the cellular IAP proteins 1 and 2 (cIAP1 and 2), which are E3 ubiquitin ligases that primarily regulate programmed cell death signaling pathways engaged by immune cytokines [3] [4] [5] [6] [7] [8] [9] , causes TNF-α, TRAIL and interleukin 1 beta (IL-1β) to become toxic to the majority of cancer cells [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
An important property of SMCs is that they target several IAPs, including XIAP and the cIAPs; as such, SMC therapy intervenes at multiple distinct yet interrelated stages in the inhibition of programmed cell death. This characteristic imbues SMC therapy with two noteworthy advantages over most other molecularly targeted drugs: fewer opportunities for tumors to develop resistance, and more opportunities for synergy with existing and emerging cancer therapeutics, many of which activate pro-apoptotic pathways influenced by SMCs. For example, inflammatory cytokines such as TNF-α and IL-1β and pro-apoptotic proteins such as TRAIL potently synergize with SMC therapy in many tumor-derived cell lines in vitro. Therapeutic strategies aimed at increasing the abundance of these pro-apoptotic proteins in SMC-treated tumors, using approaches, in particular, that would limit the toxicities commonly associated with recombinant cytokine therapy, are thus very attractive.
TNF-α, TRAIL and dozens of other cytokines and chemokines are upregulated in response to pathogen recognition by the innate immune system [17] [18] [19] . Notably, this ancient response to microbial invaders is usually self-limiting and safe, due to stringent negative regulation that limits the strength and duration of its activity. We thus asked whether stimulating the innate immune system using pathogen mimetics would be a safe and effective strategy to generate a cytokine milieu sufficient to initiate programmed cell death in tumors treated with an SMC. We report here that nonpathogenic oncolytic viruses, as well as mimetics of microbial RNA or DNA (poly(I:C) and CpG, respectively) induce bystander killing of cancer cells treated with an SMC, and that this death depends on IFN-β, TNF-α and/or TRAIL production. Importantly, this combinatorial therapeutic strategy was tolerable in vivo in mice and led to durable cures in several mouse models of aggressive cancer.
RESULTS

Synergistic induction of bystander cell death
Oncolytic viruses are currently in phases 1-3 clinical evaluation in cancer patients 20 . A major barrier to effective oncolytic virus therapy is virus-induced expression of type I IFN and nuclear factor kappa B (NF-κB)-responsive cytokines, which orchestrate an antiviral state in tumors. We sought to exploit these cytokines to induce programmed cell death in cancer cells that were treated with an SMC. To begin, smac mimetics and innate immune stimuli synergize to promote tumor death A r t i c l e s we screened a small panel of tumor-derived human and mouse (n = 28) and normal (n = 2) cell lines for responsiveness to the SMC LCL161 and the oncolytic rhabdovirus vesicular stomatitis virus (VSV)∆51. We chose LCL161 because this compound is the most clinically advanced drug in the SMC class [21] [22] [23] and VSV∆51 because it is known to induce a robust antiviral cytokine response 24 . In 15 of the 28 tumor cell lines tested (54%), SMC treatment reduced the half-maximal effective concentration (EC 50 ) of VSV∆51 by 10-to 10,000-fold ( Supplementary Fig. 1 and representative examples in Fig. 1a,b) . Similarly, low dose VSV∆51 reduced the EC 50 of SMC from undetermined levels (>2,500 nM) to 4.5 and 21.9 nM in mouse mammary carcinoma EMT6 and human glioblastoma SNB75 cells, respectively ( Fig. 1c) . Combination index analyses determined that the interaction between SMC and VSV∆51 was synergistic ( Supplementary  Fig. 2 ). Experiments using four other SMCs and five other oncolytic viruses showed that all tested monomer and dimer SMCs (containing one or two IAP binding motifs, respectively) synergize with VSV∆51 in inducing EMT6 and SNB75 cell death (Supplementary Fig. 3 ). The oncolytic rhabdoviruses VSV∆51 and Maraba-MG1 were superior in eliciting bystander killing with SMCs compared to herpes simplex virus (HSV), reovirus, vaccinia and wild-type VSV ( Supplementary  Fig. 4 ); this may be explained by the fact that the latter four viruses can use elaborate mechanisms to suppress innate immune signaling 20 . RNA interference (RNAi)-mediated silencing of XIAP and the cIAPs demonstrated that synergy with VSV∆51 required silencing of both XIAP and the cIAPs (Supplementary Fig. 5) . In contrast to the results in tumor-derived cell lines, noncancer GM38 primary human skin fibroblasts and human skeletal muscle myoblasts were unaffected by VSV∆51 and SMC combination therapy ( Supplementary Fig. 1 ). Taken together, these data indicate that oncolytic VSV synergized with SMC therapy specifically in tumor cells.
To determine if VSV∆51 elicits bystander cell death in neighboring uninfected cells, we treated cells with SMCs before infection with a low dose of VSV∆51 (multiplicity of infection (MOI) = 0.01 infectious particles per cell). Immunofluorescent colocalization analyses revealed that the majority of uninfected EMT6 cells stained positive for cleaved caspase-3 ( Fig. 1d) , a marker of apoptosis; these findings suggest the induction of widespread bystander cell death. To complement this experiment, we assessed whether conditioned media derived from cells infected with VSV∆51 (which was subsequently 
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A r t i c l e s inactivated by UV light) could induce death when transferred to a plate of uninfected cancer cells treated with an SMC. The conditioned media induced cell death only when the cells were treated at the same time with an SMC (Fig. 1e) . We also found that a low dose of a pseudotyped strain, VSV∆51∆G (containing a deletion of the gene encoding its glycoprotein), that limits the virus to a single round of infection, was toxic to an entire plate of cancer cells treated with an SMC (Fig. 1f ). Finally, we performed a cytotoxicity assay in cells overlaid with agarose, which retards the spread of virus; we infected these cells with VSV∆51 expressing a fluorescent tag 25, 26 , and observed death of SMC-treated cells outside of the zone of virus infection ( Fig. 1g and Supplementary Fig. 6 ). Overall, these results indicate that VSV∆51 infection led to the release of at least one soluble factor that potently induced bystander cell death in neighboring, uninfected cancer cells treated with SMCs.
SMCs do not suppress antiviral immunity
Mammalian cells respond to infection with an RNA virus through a signaling cascade initiated by members of a family of cytosolic (RIG-I-like receptors, RLRs) and endosomal (toll-like receptors, TLRs) viral RNA sensors 27 . Once triggered, these receptors activate IFN-response factor (IRF) 3/7 and NF-κB, which results in production of IFNs and IFN-responsive genes as well as an array of inflammatory chemokines and cytokines. This response 'warns' neighboring cells of an impending virus encounter, prompting those cells to preemptively express antiviral genes; it also promotes recruitment and activation of immune cells with the ability to clear the virus infection. Because the cIAP proteins were recently implicated in innate immune signaling pathways including those emanating from RLRs and TLRs 6,8 , we asked whether SMC therapy alters the antiviral response to oncolytic VSV infection in tumor cells and in mice. First, we evaluated the effect of SMC therapy on VSV∆51 replication and spread. Single-step and multistep virus growth curves revealed that SMC treatment did not affect the kinetics of VSV∆51 growth in EMT6 or SNB75 cells in vitro ( Fig. 2a) . Similarly, timelapse microscopy showed that SMC treatment did not alter VSV∆51 infectivity in or spread through tumor cells in vitro ( Fig. 2b) . We analyzed viral replication and spread in vivo by determining abundance of virus within tumor and normal tissue using an in vivo imaging system (IVIS) and tissue virus titration. We found no differences in the kinetics of viral spread in vehicle-or SMC-treated EMT6 tumor-bearing mice ( Supplementary Fig. 7) . These data provide indirect evidence that SMC treatment did not markedly affect the antiviral response of cancer and normal cells.
To directly analyze the antiviral response, we measured IFN-β production in EMT6 and SNB75 cells treated with VSV∆51 and SMCs. SMC-treated cancer cells responded to VSV∆51 by secreting IFN-β ( Fig. 2c) , although in slightly lower amounts than vehicle-treated cancer cells. However, quantitative RT-PCR analysis of a small panel of IFN-stimulated genes (ISGs) in cells treated with VSV∆51 and vehicle or SMC revealed that SMC treatment did not markedly affect ISG gene expression ( Fig. 2d) . Consistent with this finding, western blot analyses indicated that SMC treatment did not alter IFN-β-induced STAT1 phosphorylation ( Fig. 2e) . Finally, an IFN bioassay was used to measure the extent of protection of cells against cytopathic wild-type VSV. Supernatants obtained from EMT6 cells that were pretreated with SMC and VSV∆51 provided protection against virus-induced cell death ( Fig. 2f) , thus demonstrating that SMC therapy did not alter the capacity of tumor cells to generate an antiviral response upon VSV∆51 infection. Collectively, these data demonstrate that SMCs did not impede the ability of tumor cells to sense and respond to infection with VSV∆51.
Mechanisms of bystander cell death
We previously showed that SMCs sensitize a number of cancer cell lines toward caspase-8-dependent apoptosis induced by TNF-α, TRAIL and IL-1β 15, 16 . As RNA viruses trigger the production of these cytokines, we investigated the involvement of cytokine signaling in death induced by combinatorial treatment with SMC and oncolytic virus. First, we treated cells with short interfering RNA (siRNA) specific for the TNF receptor TNF-R1 and/or the TRAIL receptor DR5. This experiment revealed that TNF-α and TRAIL were indispensable for bystander cell death induced by SMC and VSV∆51 ( Fig. 3a and Supplementary  Fig. 8a) . Western blot and immunofluorescence experiments revealed strong activation of the extrinsic apoptosis pathway; consistent with this, RNAi knockdown of caspase-8 and Rip1 revealed roles for these proteins in the bystander cell death induced by SMC and VSV∆51 (Supplementary Fig. 9 ). VSV∆51, engineered to express TNF-α, boosted cell death by an order of magnitude ( Supplementary Fig. 10 ), further solidifying a role for this cytokine in the efficacy of SMCs.
Next we silenced the type I IFN receptor (IFNAR1) and found, quite unexpectedly, that IFNAR1 knockdown prevented the synergy between SMC therapy and oncolytic VSV ( Fig. 3b and Supplementary  Fig. 8b ). We predicted that IFNAR1 knockdown would dampen bystander killing, as TRAIL is a well-established ISG downstream of type I IFN signaling 28 . However, as TNF-α and IL-1β are considered to be independent of IFN signaling (although responsive to NF-κB signaling downstream of virus detection), we predicted that IFNAR1 knockdown would not completely suppress bystander killing 29 . This result suggests the possibility of a noncanonical type I, IFN-dependent pathway regulating the production of TNF-α and/or IL-1β. Indeed, when we measured expression of transcripts encoding IFN-β, TRAIL, TNF-α and IL-1β during an oncolytic VSV infection, we found a significant temporal lag between the induction of IFN-β and that of both TRAIL and TNF-α ( Fig. 3c) . These data also suggest that TNF-α-like TRAIL-may be induced secondarily to IFN-β. To test this hypothesis, we treated cells with IFNAR1 siRNA before treating them with VSV∆51. IFNAR1 knockdown completely abrogated the VSV∆51-induced expression of both TRAIL and TNF-α ( Fig. 3d) . Moreover, recombinant type I (IFN-α/β) or type II IFN (IFN-γ), but not type III IFN (IL28/29), effectively substituted for VSV∆51 in synergizing with SMC to induce bystander killing ( Fig. 3e) .
To further explore this noncanonical pathway leading to induction of TNF-α and TRAIL, we measured TRAIL and TNF-α mRNA expression in SNB75 cells treated with recombinant IFN-β. Both cytokines were induced by IFN-β treatment ( Fig. 3f ) and enzymelinked immunosorbent (ELISA) experiments confirmed the production of their respective protein products in the cell culture media (Fig. 3g) . Interestingly, there was a significant time lag between the induction of TRAIL and that of TNF-α. As TRAIL is a bona fide ISG and TNF-α is not, this result raised the possibility that TNF-α is not induced by IFN-β directly, but responds to a downstream ISG upregulated by IFN-β. We thus performed quantitative RT-PCR on 176 cytokines in SNB75 cells and identified 70 that displayed a threefold increase of gene expression by IFN-β treatment ( Supplementary  Table 1 ). We are currently investigating the potential roles of these ISGs in the induction of TNF-α by IFN-β. Notably, SMC treatment potentiated the induction of both TRAIL and TNF-α by IFN-β in SNB75 cells ( Fig. 3f,g) . For example, in EMT6 cells, SMC treatment enhanced VSV-induced TNF-α production by five-to sevenfold (Supplementary Fig. 11 ). Furthermore, using a dominant-negative construct of IKK, we found that the production of these inflammatory cytokines downstream of IFN-β was dependent, at least in part, on classical NF-κB signaling (Fig. 3h) . Finally, blocking TNF-R1 signaling npg A r t i c l e s (with antibodies or siRNA) prevented EMT6 cell death in the presence of SMC and VSV∆51 or IFN-β ( Supplementary Fig. 12 ).
In vivo synergistic effects
To evaluate SMC and oncolytic VSV co-therapy in vivo, we first used the EMT6 mammary carcinoma as a syngeneic, orthotopic model. Preliminary safety and pharmacodynamic experiments revealed that a dose of 50 mg/kg LCL161 delivered by oral gavage was well tolerated by mice (transient loss of ~5% body weight that is recovered within 5 d) and induced cIAP1/2 knockdown in tumors for at least 24 h, and up to 48-72 h in some cases. The reduction in XIAP levels was not as pronounced ( Supplementary Fig. 13 ). When tumors reached ~100 mm 3 , we began treating mice twice weekly with vehicle or 50 mg/kg LCL161 (oral) and/or 5 × 10 8 plaque-forming units (PFU) VSV∆51 (intravenous (i.v.)). LCL161 therapy alone decreased the rate of tumor growth and modestly extended survival, whereas VSV∆51 alone did not markedly alter tumor growth or mouse survival (Fig. 4a,b) . However, combined SMC and VSV∆51 treatment induced tumor regression and led to durable cures in 40% of the treated mice. Consistent with the bystander killing mechanism elucidated in vitro, immunofluorescence analyses revealed that the infectivity of VSV∆51 was transient and limited to small foci within the tumor (Fig. 4c) , Error bars, mean ± s.d. n = 3. (e) Cells were pretreated with 5 µM LCL161 for 2 h and subsequently stimulated with IFN-β for the indicated times. Total and phosphorylated STAT1, cIAP1/2 knockdown and β-tubulin (loading control) was measured by western blot analysis. (f) EMT6 cells were treated with vehicle or 5 µM LCL161 and infected with the indicated MOI of VSV∆51 for 20 h. Media was exposed to UV light and then applied to uninfected cells. Cells were subsequently challenged with 1 MOI of wild-type VSV for 48 h and the proportion of rescue of cell death from wild-type VSV was measured by an Alamar blue viability assay. Error bars, mean ± s.d. n = 3. All figure panels: representative data from at least three independent experiments using biological replicates. npg A r t i c l e s whereas caspase-3 activation was widespread in tumors cotreated with SMC and VSV∆51 (Fig. 4d) . Furthermore, western blots of tumor lysates demonstrated activation of caspase-8 and caspase-3 in doubletreated tumors (Fig. 4e) . Although the animals in the combination treatment cohort lost weight, the mice fully recovered after the last treatment (Supplementary Fig. 14a ).
To confirm these in vivo data in another model system, we tested the human HT-29 colorectal adenocarcinoma xenograft model in nude (athymic) mice. HT-29 is a cell line that is highly responsive to bystander killing by SMC and VSV∆51 cotreatment in vitro (Supplementary Fig. 15a,b) . Similar to our findings in the EMT6 model system, combination therapy with 50 mg/kg LCL161 (oral) and 1 ×10 8 PFU (intratumoral) of VSV∆51 slowed tumor growth and led to a significant extension of mouse survival ( Supplementary  Fig. 15c) . In contrast, neither monotherapy had any effect on HT-29 tumors. Furthermore, there was no additional weight loss in the double-treated mice compared to SMC-treated mice ( Supplementary  Fig. 15d) . These results in the HT-29 model indicate that the synergy between SMC and VSV∆51 does not completely require the adaptive immune response.
Next, we wished to determine whether oncolytic virus infection coupled with SMC treatment leads to TNF-α-and/or IFN-β-mediated cell death in vivo. Compared to an isotype control antibody, TNF-α neutralizing antibody prevented SMC and VSV∆51-induced EMT6 tumor regression and mouse survival extension ( Fig. 4f,g) . However, treatment of BALB/c mice bearing EMT6 tumors with IFNAR1-blocking antibodies resulted in mouse death due to viremia within 24-48 h after infection. Nevertheless, before mouse death and 18-20 h after virus infection, we collected tumors and analyzed caspase activity. Compared to SMC and VSV∆51-treated mice injected with isotype control antibody, those injected with anti-IFNAR1 showed no caspase-8 activity and much less caspase-3 activity ( Supplementary  Fig. 16) . These results support the hypothesis that intact TNF-α and type I IFN signaling was required to mediate the in vivo anti-tumor effects of the combinatorial treatment.
To assess the contribution of innate immune cells or other immune mediators to the efficacy of combination therapy, we first attempted to treat EMT6 tumors in immunodeficient nonobese-severe combined immune deficiency (NOD-SCID) or NSG (NOD-scid-IL2Rgamma null ) mice. However, similar to mice treated with anti-IFNAR1, these mice died rapidly due to viremia (data not shown). Therefore, we addressed the contribution of innate immune cells in an ex vivo splenocyte culture system. Sorted splenic macrophages (CD11b + F4/80 + ), neutrophils (CD11b + Gr1 + ), natural killer (NK) cells (CD11b − CD49b + ) and nonmyeloid (CD11b − CD49 − ) populations were stimulated with VSV∆51, and the conditioned medium was transferred to EMT6 cells treated with vehicle or SMC. VSV∆51-stimulated macrophages and neutrophils, but not NK cells, A r t i c l e s produced factors that led to cancer cell death in the presence of SMCs (Supplementary Fig. 17a ). We also isolated primary macrophages from bone marrow and these macrophages also responded to oncolytic VSV infection in a dose-dependent manner to produce factors that kill EMT6 cells (Supplementary Fig. 17b ). Altogether, these findings demonstrate that multiple innate immune cell populations can mediate the observed anti-tumor effects, but that macrophages may be the most likely effectors of this response. 
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A r t i c l e s Adjuvants potentiate SMC effects in vivo We next investigated whether synthetic TLR agonists (often used as adjuvants) known to induce an innate proinflammatory response could replace oncolytic virus and synergize with SMCs. We co-cultured EMT6 cells with mouse splenocytes in a transwell insert system, and treated the splenocytes with SMC and agonists of TLR 3, 4, 7 or 9. All of the tested TLR agonists induced the bystander death of SMCtreated EMT6 cells (Fig. 5a) . The TLR4, 7 and 9 agonists LPS, imiquimod and CpG, respectively, required splenocytes to induce bystander killing of EMT6 cells, presumably because their target TLR receptors are not expressed in EMT6 cells. However, the TLR3 agonist poly(I:C) led to EMT6 cell death in the absence of splenocytes.
We next tested poly(I:C) and CpG in combination with SMC therapy in vivo. We chose these adjuvants as they have proven to be safe in humans and are currently being evaluated in numerous mid-to late-stage clinical trials for cancer [30] [31] [32] [33] . EMT6 tumors were established and treated as described above. Whereas poly(I:C) treatment had no bearing on tumor growth as a single agent, when combined with SMCs it induced substantial tumor regression and, when delivered intraperitoneally, led to durable cures in 60% of the treated mice 
A r t i c l e s ( Fig. 5b,c) . Whereas CpG monotherapy moderately reduced tumor growth and extended survival, when combined with SMC treatment, a significant regression in tumor growth and an increase in durable cures were observed in 88% of the treated mice ( Fig. 5d,e) . Markedly, the most effective therapy was with the combination of SMC with local (intratumoral) and systemic (i.v.) administration of CpG, presumably because of the increased concentration of proinflammatory cytokines within the tumor milieu. Importantly, these combination therapies were well tolerated by the mice, and their body weight returned to pretreatment levels shortly after the cessation of therapy ( Supplementary  Fig. 14b,c) . Together these data demonstrate that a series of clinically advanced innate immune adjuvants strongly and safely synergize with SMC therapy in vivo.
DISCUSSION
SMC medicines are rapidly progressing through clinical evaluation; however, SMCs will likely require rationally designed therapeutic partners to be maximally effective 1 . Here we demonstrate a new strategy for boosting the efficacy of SMC therapy, specifically the stimulation of a host innate immune response. Our approach is broadly useful in that it works with different SMCs and a number of pathogen mimetics in a large percentage of examined tumor cell lines. In addition, this combinatorial approach was efficacious in various aggressive, treatment-refractory, murine tumor models. Several of the SMCs studied here are in early-to mid-stage clinical evaluation and all of the pathogen mimetics/adjuvants examined here are currently in phase 1-3 clinical trials 23, [30] [31] [32] [33] [34] [35] . Data from the human studies have indicated that each of these medicines is safe 23, 34, 35 , but none appear to be particularly effective as monotherapies. Our strategy overcomes the limitations of both Smac and pathogen mimetics as single agents, at least in cell-based and murine model systems. Type I IFNs, including the therapeutically relevant cytokines IFN-α and IFN-β, were effectors of SMC-induced tumor killing. This unexpected discovery will ultimately shed light on IFN biology and death pathways involving caspase-8, which are controlled by the cIAPs and XIAP, and which can now be further explored and exploited therapeutically in combination with SMCs. The relationship between type I IFN and TNF-α is complex, as these two cytokines have complementary or opposing effects depending on the biological context 36, 37 . However, in the context of SMC plus oncolytic virus treatment, a simple working model can be proposed ( Supplementary  Fig. 18 ). Tumor cells infected by an oncolytic RNA virus upregulate type I IFN, and this process is not affected by SMC antagonism of the IAP proteins. Those IFNs in turn signal to the same cancer cell (autocrine) and neighboring uninfected cancer cells (paracrine) and induce secretion of TNF-α and TRAIL; this process is enhanced by SMC treatment. In the presence of SMC and the cytokines TNF-α and/or TRAIL, bystander tumor cells undergo caspase-8dependent apoptosis.
Previous work indicated that an SMC can enhance the adaptive immune response against a B16 melanoma tumor by boosting cancer vaccine-induced T-cell activity 3, 4 . In contrast, our findings underscore the critical role that the innate immune response plays in this combination approach. Furthermore, although many other approaches to improve SMC therapy have been attempted, very rarely have complete responses been observed, particularly in aggressive tumors in immunocompetent mice. The one exception was cotreatment with SMC and recombinant TRAIL, which led to durable cures in at least one mouse model system 38 . We suspect that using a pathogen mimetic, whose mechanism of action is partially dependent on TRAIL, is a superior approach for two reasons. First, this approach also induces TNF-α-mediated apoptosis and necroptosis, and given the plasticity and heterogeneity of most advanced cancers, simultaneously inducing multiple distinct cell death mechanisms is more likely to be effective for treating these diseases, and resistance is less likely to develop to such treatment. Second, pathogen mimetics elicit an integrated innate immune response that includes layers of negative feedback. We suspect that these feedback mechanisms act to temper the cytokine response in ways that are difficult to replicate using recombinant proteins, and thus act as a safeguard to prevent toxicity of this combination therapy.
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